Can naltrexone be used to treat dissociation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Naltrexone for Dissociation: Not Recommended as Standard Treatment

Naltrexone should not be used as a standard treatment for dissociation, as it lacks FDA approval for this indication and has insufficient high-quality evidence supporting its efficacy. The FDA-approved indications for naltrexone are limited to alcohol use disorder and opioid use disorder 1. While emerging research suggests potential benefit, the evidence remains preliminary and inconsistent.

Evidence Assessment

Research Findings

The most recent systematic review and meta-analysis (2023) examined naltrexone for dissociative symptoms and found a pooled effect size of d = 1.46 (95% CI: 0.62-2.31), suggesting a moderate-to-large treatment effect 2. However, this analysis included only 5 comparative studies with 154 total participants, demonstrated significant heterogeneity (Q = 66.89, p < .001), and showed potential publication bias. The authors themselves emphasized that results must be interpreted with caution due to limited data and methodological heterogeneity.

Individual studies show mixed results:

  • An open trial (2005) with 14 subjects showed 30% symptom reduction at doses of 100-250 mg/day, with 4 of 14 patients showing marked improvement 3
  • A double-blind placebo-controlled trial (2012) in 29 patients with borderline personality disorder found numerically lower dissociation scores with naltrexone (50-200 mg/day) versus placebo, but differences failed to reach statistical significance 4
  • A small German study (2015) using low-dose naltrexone (2-6 mg/day) reported subjective improvement in 11 of 15 patients, though this was uncontrolled 5

Mechanistic Rationale

The theoretical basis involves endogenous opioid system dysregulation in dissociation. Naltrexone, as an opioid receptor antagonist, may modulate this system 6, 3. However, this remains speculative, and one study paradoxically found that patients taking naltrexone for opioid use disorder had lower dissociation scores compared to those on buprenorphine 7.

Clinical Considerations If Use Is Contemplated

Contraindications and Warnings (FDA Label)

  • Absolute contraindications: Current opioid use or dependence (risk of precipitated withdrawal), acute hepatitis, liver failure 1
  • Black box warnings: Hepatotoxicity with cases of clinically significant liver dysfunction reported 1
  • Depression and suicidality: Monitor closely, as depression and suicidal ideation have been reported in postmarketing surveillance 1

Dosing Considerations

Research studies have used widely varying doses:

  • Standard dose: 50-100 mg/day (FDA-approved dose for alcohol/opioid use disorder) 3
  • High dose: Up to 250 mg/day in some trials 3
  • Low dose: 2-6 mg/day (0.06 mg/kg) in one small study 5

Monitoring Requirements

  • Baseline and periodic liver function tests (every 3-6 months) 8
  • Screen for opioid use before initiation to prevent precipitated withdrawal 1
  • Monitor for emergence of depression or suicidal thinking 1
  • Assess for hepatotoxicity symptoms (jaundice, dark urine, abdominal pain) 1

Common Pitfalls

  1. Assuming efficacy based on small open-label studies: The only adequately controlled trial showed no statistically significant benefit 4

  2. Overlooking hepatotoxicity risk: Naltrexone can cause liver injury, particularly at higher doses 1

  3. Using in patients with unrecognized opioid use: This can precipitate severe withdrawal 1

  4. Expecting rapid improvement: Even in positive studies, effects were modest and required weeks of treatment 3

  5. Neglecting that reduced dissociation may be destabilizing: Dissociation often serves a protective function in trauma survivors; its reduction without adequate psychotherapeutic support may overwhelm patients 5

Alternative Approach

Prioritize evidence-based psychotherapy for dissociative symptoms, which remains the gold standard. If pharmacotherapy is considered for comorbid conditions (depression, PTSD, anxiety), use medications with established efficacy for those specific diagnoses. Naltrexone may be considered only in research settings or as an off-label option in treatment-refractory cases after thorough informed consent discussion about limited evidence, potential risks, and need for close monitoring.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.